Drug Trial Radar · NCT06712823
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 25, 2025
Primary completion
Jul 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
Conditions
- Congenital Adrenal Hyperplasia
- Classic Congenital Adrenal Hyperplasia
Interventions
atumelnant (CRN04894)Drug
Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), adverse events of special interest (AESI [adrenal insufficiency]) and any adverse events (AEs) leading to discontinuationTime frame: Week 108
- Incidence of glucocorticoid (GC) deficiency / adrenal insufficiency and adrenal crisisTime frame: Week 108
- Incidence of hospitalizations related to congenital adrenal hyperplasia (CAH)Time frame: Week 108
- Change from baseline in morning (before 11:00 AM) serum androstenedione (A4) over timeTime frame: Week 108
Locations
13 sites in 6 countries. Site status is shown where the registry gives one.
Crinetics Study Site, Minneapolis, Minnesota 55454
Minneapolis, Minnesota · Active not recruiting
Crinetics Study Site
Morehead City, North Carolina · Active not recruiting
Crinetics Study Site
Philadelphia, Pennsylvania · Active not recruiting
Crinetics Study Site
Córdoba, Córdoba Province, Argentina · Recruiting
Crinetics Study Site
Rio de Janeiro, Brazil · Recruiting
Crinetics Study Site
São Paulo, Brazil · Recruiting
Crinetics Study Site
Curitiba, Paraná, Brazil · Recruiting
Crinetics Study Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Crinetics Study Site
Botucatu, São Paulo, Brazil · Recruiting
Crinetics Study Site
Munich, Bavaria, Germany · Recruiting
Crinetics Study Site
Roma, Italy · Recruiting
Crinetics Study Site
Birmingham, United Kingdom · Recruiting
Crinetics Study Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.